Announced Thu, 23 Jul · 16:29 IST
Board approves in-principle evaluation of radiology arm demerger
Strategic Transactions View source PDF
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.0%1-day move
₹544.95
prior close
₹560.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+5.4+3.1+1.3+4.2+7.0—————————
Up moveDown movePending
AI summary
Thyrocare's Board has in-principle approved evaluating the demerger of the radiology business of its wholly owned subsidiary Nueclear Healthcare (which runs PET-CT and CT imaging centres and makes radiopharmaceuticals) to a party outside the group. The restructuring could be via scheme of arrangement, slump sale, or business transfer. Currently at evaluation stage only with no final terms yet. Subject to regulatory and statutory approvals.
Likely market impact
Signals portfolio reshaping. Radiology is a smaller arm of Thyrocare. Watch for valuation, structure, and regulatory progress on the proposed deal.